Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

The Peptide Effect

The Peptide Effect artwork

Apolipoprotein-Targeting Peptides: The Future of Cholesterol, Brain Health, and Longevity

Jun 27, 202633 minAudio

Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! In this episode of The Peptide Effect, we explore the emerging world of apolipoprotein-targeting peptides and how they’re reshaping the future of cardiovascular and neurological research. Learn how apolipoproteins transport cholesterol throughout the body, why HDL function may be just as important as HDL levels, and how experimental peptides such as 4F, 5A, ATI-5261, FAMP, CN-105, and D6PV are being investigated for their potential to improve cholesterol metabolism, reduce inflammation, protect the brain, and support healthy aging. We’ll also discuss reverse cholesterol transport, ApoA-I, ApoE, ApoC-II, and the role these peptides may play in the future of precision medicine. Whether you’re interested in peptide science, longevity, heart health, or cutting-edge biomedical research, this episode offers a comprehensive introduction to one of the newest frontiers in peptide therapeutics.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

This podcast is intended for educational and informational purposes only. It is not medical advice and should not be used to diagnose, treat, cure or prevent any disease. Many of the compounds discussed today are investigational and have not been approved for general medical use. Always consult a qualified healthcare professional before making decisions about your health or using any medication, peptide or research compound. Welcome back to the peptide effect. Today we're taking a deep dive into one of the newest and most exciting

areas of peptide research, apolipoprotein -targeting peptides. While compounds like BPC, 157, GHKCU, MOS -C, and SS 31 have become well known among peptide enthusiasts, apolipoprotein -targeting peptides remain relatively unknown outside of research laboratories. Yet many scientists believe these compounds could eventually change the way we think about cardiovascular disease, metabolic health, inflammation, and even neurological disorders.

To understand why these peptides are attracting so much attention, we first need to understand what apolipoproteins actually are. When most people hear the word cholesterol, they immediately think of something negative. Cholesterol has been blamed for heart attacks, strokes, clogged arteries, and countless other health problems. But cholesterol itself is not the enemy. In fact, your body couldn't survive without it. Every single cell in your body contains cholesterol. Your body uses cholesterol to build cell membranes,

manufacture steroid hormones such as testosterone and estrogen, produce cortisol, create vitamin D and synthesize bile acids that allow you to digest dietary fats. Without cholesterol, life simply wouldn't exist. The challenge isn't cholesterol itself. The challenge is getting cholesterol to the right place at the right time while removing excess cholesterol before it begins causing problems. This is where apolipoproteins enter the picture. Imagine that your bloodstream is a massive interstate

highway system. Instead of transporting cars, it's transporting tiny packages of fat. Those packages include cholesterol, triglycerides, phospholipids and fat -soluble vitamins. Because fat doesn't dissolve well in water, These packages need specialized transportation vehicles. Those transportation vehicles are called lipoproteins. You have probably heard of HDL and LDL. Those are both examples of lipoproteins. Now imagine each delivery truck has a GPS system, a shipping

label, a security badge, and a key that allows it to dock at specific destinations. Those identifiers are the apolipoproteins. Without them, the delivery trucks would have no idea where to go. Apolipoproteins determine where cholesterol travels, which cells receive it, how quickly it's removed, and how efficiently excess cholesterol returns to the liver for disposal. Researchers have identified dozens of different apolipoproteins, each with unique responsibilities. Some activate enzymes.

Others bind to receptors. Some regulate triglyceride metabolism. Others coordinate cholesterol recycling. The remarkable thing is that scientists realized they don't necessarily need to recreate the entire protein to gain some of its benefits. Instead, they can identify the most biologically active portions of these proteins and recreate only those segments as peptides. That approach is what gave birth to apolipoprotein -targeting peptides. Instead of manufacturing enormous complex proteins, researchers build much smaller peptide

fragments that imitate specific functions of the parent protein. These memetic peptides often have advantages over full -length proteins. They're easier to manufacture, easier to modify, sometimes more stable, and in some cases they may penetrate tissues more effectively. The first major focus became a protein called apolipoprotein A1, commonly shortened to OPOA1. OPOA1 is the primary protein found on HDL particles. HDL is commonly called

good cholesterol, but that nickname doesn't fully explain what it actually does. Think about your neighborhood after a storm. Debris is scattered everywhere. Fallen branches, trash, damaged materials and broken objects cover the streets. Imagine a fleet of cleanup trucks moving through the neighborhood collecting the debris before it causes further problems. That's very similar to what HDL does inside your body. As cells naturally use cholesterol, Oxidized cholesterol and excess lipids began accumulating within tissues, especially

inside artery walls. HDL particles help collect that excess cholesterol and transport it back to the liver through a process called reverse cholesterol transport. This process is incredibly important because cholesterol buildup inside artery walls contributes to plaque formation. For years, researchers focused primarily on lowering LDL cholesterol. While lowering LDL remains extremely important, scientists eventually realized another question deserved attention. What if we could make HDL work better? What if instead of simply

increasing HDL numbers, we improved HDL function? Those questions inspired decades of research. Scientists discovered certain regions within OpoA1 were responsible for many of its beneficial activities. That discovery eventually led to one of the most famous OpoA1 memetic peptides ever developed. It was called 4F. The name comes from four phenylalanine amino acids positioned strategically within the peptide sequence. 4F demonstrated an impressive ability to bind oxidized

lipids. Oxidized lipids are particularly dangerous because they trigger inflammation throughout blood vessel walls. When LDL particles become oxidized, Immune cells recognize them almost like foreign invaders. Macrophages begin engulfing these oxidized particles. Eventually those macrophages become overloaded with cholesterol. At that point they transform into foam cells. Foam cells accumulate inside artery walls and become one of the earliest building blocks of atherosclerotic plaque. Researchers

discovered 4F could bind oxidized lipids remarkably well. Instead of allowing these inflammatory lipids to continue damaging tissues, the peptide appeared capable of helping neutralize them. Over time, researchers developed multiple versions. One version used naturally occurring amino acids. Another version used mirror image amino acids called deamino acids. This became known as D4F. Why create a mirror image version? because digestive enzymes recognize naturally occurring amino acids

much more easily. Mirror -image amino acids resist digestion far better. That meant D4F showed potential for oral administration, something that remains relatively uncommon among peptide therapeutics. While much research remains ongoing, D4F became one of the best -known OpoA1 mimetic peptides in cardiovascular research. Scientists then continued improving their designs. Another peptide known as 5A attempted to optimize cholesterol removal while minimizing unwanted interactions with cell

membranes. In laboratory studies, 5A demonstrated promising effects on cholesterol efflux. Cholesterol efflux simply means moving cholesterol out of cells. Imagine trying to empty water from a flooded basement. The faster you remove the water, the less damage occurs. Researchers hope improving cholesterol efflux may similarly reduce long -term damage in side arteries. Another interesting peptide is ATI -5261. This peptide was engineered

specifically to imitate important characteristics of OPOA1 while remaining relatively compact and stable. Animal studies suggested improvements in HDL function and reverse cholesterol transport. Researchers also developed a peptide known as FEMP, which stands for Fukuoka University ApoA1 Mimetic Peptide. Although the name isn't particularly catchy, its research has attracted considerable attention. FEMP appeared capable of improving HDL functionality rather than simply raising

HDL cholesterol measurements. That distinction is becoming increasingly important. Imagine two garbage trucks. One truck is enormous, but never actually picks up garbage. The other truck is smaller but constantly removes trash efficiently throughout the city. Which one would you rather have? Researchers increasingly believe HDL works much the same way. Function matters just as much, and perhaps even more, than quantity. That realization has fundamentally changed cardiovascular research.

For decades, pharmaceutical companies attempted to raise HDL cholesterol numbers. Many of those drugs increased HDL levels substantially. Unfortunately, several failed to reduce cardiovascular events as much as researchers hoped. Why? Because increasing HDL quantity doesn't necessarily improve HDL quality. The HDL particles must still perform their clean -up job efficiently. That is precisely where OpoA1 mimetic peptides may eventually prove valuable. They focus less on creating bigger

numbers and more on improving performance. Another fascinating aspect involves inflammation. For many years, cardiovascular disease was viewed almost entirely as a cholesterol problem. Today we know inflammation plays a massive role. Inflammation contributes to endothelial dysfunction, oxidative stress, plaque instability, immune activation, and eventually cardiovascular events. Many OpoA1 mimetic peptides appear capable of reducing inflammatory signaling in addition to improving lipid transport.

That dual mechanism has generated significant excitement. Researchers are no longer asking only how to lower cholesterol. They're asking how to improve the entire environment surrounding blood vessels. Healthy blood vessels depend upon balanced inflammation, efficient cholesterol transport, proper nitric oxide production, and healthy endothelial cells. Apolipoprotein -targeting peptides may eventually influence several of those pathways simultaneously. That's one reason many researchers consider them such an exciting

frontier. The story becomes even more interesting once we move beyond APOA. Another apolipoprotein has become one of the hottest subjects in neuroscience. That protein is APOA. Unlike APOA1, which primarily functions in HDL metabolism, APO performs numerous responsibilities throughout the body. Perhaps its most fascinating role occurs inside the brain. The brain contains an enormous amount of cholesterol. However, brain cholesterol operates almost independently

from cholesterol circulating elsewhere in the body because of the blood -brain barrier. Neurons require cholesterol for membrane maintenance, synapse formation, nerve repair, and countless other functions. APO serves as one of the primary transport proteins responsible for moving cholesterol between brain cells. It also helps regulate immune activity within the central nervous system. Researchers discovered decades ago that genetics involving APO dramatically influence Alzheimer's disease risk. People carrying the APO 4 variant have

a substantially greater lifetime risk of developing Alzheimer's disease compared with those carrying APO 3 or APO 2. That discovery transformed neuroscience. Scientists immediately began asking whether they could mimic the beneficial functions of Apo without reproducing every aspect of the full protein. That question eventually led to the development of apomimetic peptides. One of the most promising is called CN105. CN105 is one of the most clinically

advanced apolipoprotein -targeting peptides currently under investigation. Unlike the full APO protein, which is very large and complex, CN105 is a short peptide designed to capture some of APO's most beneficial biological activities. One reason researchers became interested in this peptide is because of the body's inflammatory response following injuries to the brain. Whether someone experiences a traumatic brain injury, a stroke, or bleeding within the brain, the initial injury

is only part of the problem. The body then mounts an inflammatory response that, while intended to help, can sometimes cause additional damage. Scientists often refer to this as secondary injury. Cells release inflammatory molecules, immune cells become activated, swelling develops, and the blood -brain barrier can become compromised. All of these events may contribute to further injury after the original event has already occurred. Researchers discovered that APO naturally helps

regulate many of these inflammatory processes. That led to the obvious question, could a peptide that mimics APO help reduce some of the secondary damage? Early laboratory studies suggested the answer might be yes. CN105 appeared capable of reducing neuroinflammation, preserving the integrity of the blood -brain barrier, decreasing brain swelling, and improving neurological recovery in several experimental models. Those encouraging findings eventually led to human clinical trials.

Although research is still ongoing and much remains to be learned, CN105 has become one of the leading examples of how apolipoprotein -targeting peptides may eventually expand beyond cardiovascular medicine into neurology. Researchers have explored its potential use following intracerebral hemorrhage, traumatic brain injury, subarachnoid hemorrhage and other neurological conditions. That raises another fascinating possibility. Many chronic neurological diseases involve persistent inflammation.

Conditions like Alzheimer's disease, Parkinson's disease, multiple sclerosis, and several other neurodegenerative disorders all involve inflammatory pathways to varying degrees. That does not automatically mean apomimetic peptides will become treatments for these diseases. Those questions still require extensive research. However, scientists are actively investigating whether modifying inflammatory signaling inside the brain could improve long -term neurological health. This is an important

reminder that peptides are often much more than simple growth factors or hormones. Many peptides function as biological messengers. They influence communication between cells. They activate receptors. They regulate immune responses. They coordinate repair processes. Rather than forcing biology in one direction, many peptides simply encourage the body to perform functions it already knows how to perform. That concept appears repeatedly throughout peptide science. Whether we're discussing

BPC, 157, GHKCU, MOS -C, or apolipoprotein mimetics, the goal is often to enhance existing biological systems rather than replace them entirely. Another family of apolipoprotein -targeting peptides focuses on a different protein called ApoC2. While ApoA1 primarily helps with cholesterol transport and Apo has important neurological functions, ApoC2 plays a major role in triglyceride metabolism. Triglycerides are another form of

fat circulating through the bloodstream. After eating a meal containing fat, triglyceride -rich particles begin circulating through the body. To utilize those fats for energy or storage, the body relies heavily on an enzyme called lipoprotein lipase. Think of lipoprotein lipase as a pair of molecular scissors. Its job is to cut triglycerides into smaller fatty acids that cells can actually use. Here's the interesting part. Lipoprotein lipase doesn't function efficiently by itself.

It requires activation. One of the proteins responsible for activating it is apocetoo. Without adequate activation, triglycerides remain elevated within the bloodstream. Researchers recognized that if they could mimic OPPO -C2, they might improve triglyceride metabolism, especially in rare diseases where triglycerides become dangerously high. That led to experimental peptides such as D6PV. Although not widely known outside lipid research, D6PV has demonstrated the ability to activate

lipoprotein lipase and dramatically lower triglycerides in experimental settings. For patients with extremely elevated triglycerides, this could eventually become an important therapeutic strategy. Very high triglycerides don't simply increase cardiovascular risk. They can also trigger acute pancreatitis, an extremely painful and potentially life -threatening inflammation of the pancreas. Reducing triglycerides rapidly can therefore have important medical implications. Researchers have also developed

additional Oppo C2 mimetic peptides with similar goals, although most remain in earlier stages of development. As scientists continued exploring different apolipo proteins, they expanded into several other families as well. Some research has focused on Oppo A5, another protein involved in triglyceride regulation. Other investigators have explored Oppo M. Oppo -J, and even peptides designed to influence Oppo -C3 activity. Many of these remain in very early laboratory research.

Some may never become approved therapies. Others may eventually become major advances. That's one of the realities of biomedical research. For every successful drug that reaches patients, dozens or even hundreds of experimental compounds never make it through development. Failure isn't necessarily because a compound is unsafe. Sometimes it simply doesn't outperform existing therapies. Sometimes manufacturing becomes too expensive. Sometimes clinical trials fail to show sufficient

benefit. Sometimes unexpected pharmacology appears during larger studies. Research is a process of continuous refinement. One reason peptide science has accelerated dramatically over the past 20 years is our growing understanding of protein structure. Advances in molecular biology. Computational chemistry and artificial intelligence now allow scientists to predict protein interactions with increasing accuracy. Rather than relying entirely on trial and error, researchers can

model how specific amino acid sequences fold, how they bind receptors, and how modifications influence stability. This dramatically speeds peptide discovery. Scientists can now design peptides intentionally instead of discovering them entirely by accident. Small changes can produce surprisingly large effects. Replacing a single amino acid may increase stability. Adding a fatty acid chain may dramatically extend half -life. Cyclizing a peptide may improve resistance

to enzymatic degradation. Changing amino acids from the naturally occurring L -form to the mirror image D -form may improve oral stability. These kinds of molecular engineering strategies continue pushing peptide science forward. You may wonder whether apolipoprotein -targeting peptides are similar to statins. The answer is no. Statins primarily reduce cholesterol production by inhibiting an enzyme within the liver called HMgCoA reductase. Less cholesterol production generally results

in lower LDL cholesterol. Apolipoprotein -targeting peptides approach the problem from an entirely different direction. Instead of focusing on cholesterol production, They focus on cholesterol transport, cholesterol recycling, inflammatory signaling, lipid oxidation, receptor activation, and lipoprotein function. That doesn't necessarily make one approach superior to the other. In the future, entirely different classes of therapies may complement each other. One therapy may reduce cholesterol

production. Another may improve cholesterol removal. Another may reduce inflammation. Another may stabilize plaque. Another may improve endothelial health. Modern medicine increasingly recognizes that complex diseases often require multiple complementary approaches. The same principle already exists in diabetes treatment, cancer therapy, infectious disease management, and hypertension. Cardiovascular medicine appears to be moving in a similar direction. Researchers are beginning

to appreciate that heart disease isn't caused by a single factor. Instead, it's influenced by cholesterol, inflammation, insulin resistance, blood pressure, oxidative stress, genetics, endothelial dysfunction, immune signaling, lifestyle, nutrition, physical activity, sleep quality, smoking, environmental exposures, and many additional variables. That growing understanding helps explain why peptide research has expanded so rapidly. Peptides often interact with highly specific biological pathways

that traditional medications may not target. Their specificity is both one of their greatest strengths and one of their greatest challenges. Because peptides can be incredibly selective, they sometimes produce fewer off -target effects. However, that same specificity also means they may require careful dosing, specialized delivery systems, or combination approaches to achieve optimal benefit. As peptide technology continues improving, researchers are developing longer -lasting formulations, improved stability, alternative

delivery methods, and entirely new peptide architectures. Some peptides that once required multiple injections each day can now be administered weekly. Others are being investigated as oral formulations, nasal sprays, transdermal preparations, or long -acting depo injections. The field continues evolving at an impressive pace. When many people think about peptide research, they immediately picture muscle growth or fat loss. In reality, peptide science extends into nearly every area

of medicine including cardiology, neurology, immunology, endocrinology, gastroenterology, dermatology, infectious disease, and oncology. Apolipoprotein -targeting peptides represent an excellent example of how broad this field has become. Rather than simply making muscles larger or reducing body fat, These compounds attempt to improve some of the body's most fundamental transportation systems. They remind us that health isn't just about how much cholesterol we have. It's also about where that cholesterol goes,

how efficiently it's recycled, how inflammation is regulated, and how cells communicate with one another. As exciting as this field is, it's important to remember that apolipoprotein targeting peptides are still in the early stages of development compared to many other medications. While several have shown promising results in laboratory studies and some have advanced into human clinical trials, there are still many questions researchers are working to answer. One of the biggest questions is whether improvements seen in biomarkers will

translate into meaningful long -term health outcomes. For example, if a peptide improves cholesterol efflux, reduces oxidized lipids, or lowers inflammatory markers, that's certainly encouraging. But researchers ultimately want to know whether those changes actually reduce heart attacks, strokes, cognitive decline, or other major health events over many years. Those kinds of studies take time. They often involve thousands of participants followed over several years before enough data can be collected to draw reliable conclusions. Another

challenge involves manufacturing. Peptides are far more complex than many traditional medications. Their amino acid sequences must be assembled with extraordinary precision. Even small manufacturing differences can affect stability, purity, and biological activity. Researchers must also determine the best methods of delivery. Some peptides are rapidly broken down in the digestive system, making injections necessary. Others can be modified chemically to resist enzymatic degradation. Scientists

continue searching for ways to improve oral absorption, increase half -life, and reduce dosing frequency. The success of several newer long -acting peptide medications has demonstrated that these challenges can often be overcome with thoughtful molecular engineering. Another important consideration is cost. New biologic therapies often begin with very high manufacturing expenses. As production methods improve and patents eventually expire, costs typically decrease over time. Whether apolipoprotein

-targeting peptides become widely available in the future will depend not only on their effectiveness but also on whether they can be manufactured efficiently enough for broad clinical use. Researchers are also investigating whether these peptides may work particularly well in combination with existing therapies. For example, Imagine someone already receiving excellent LDL cholesterol control with a statin or another lipid -lowering medication. If an apolipoprotein mimetic peptide could further improve HDL function, reduce vascular inflammation,

or enhance cholesterol recycling, the combination might provide benefits that neither therapy could achieve alone. Of course, that's only a possibility at this stage. Those questions require carefully designed clinical trials before any conclusions can be reached. One area generating considerable interest is personalized medicine. Medicine has traditionally followed a fairly standardized approach. Many patients with the same diagnosis receive similar treatments. Today, researchers increasingly recognize that individuals often

respond very differently because of genetics, metabolism, immune function, lifestyle, and environmental factors. Apolipoproteins themselves are an excellent example. Different versions of the apo gene influence lipid metabolism, inflammation, and neurological disease risk in different ways. As genetic testing becomes more common and more affordable, physicians may eventually be able to tailor therapies based on an individual's specific genetic profile. Instead of asking only what disease a person

has, future medicine may ask why that individual developed the disease in the first place and which biological pathways are most important in that particular person. That represents a significant shift in medical thinking. Rather than applying one treatment to everyone, therapies may become increasingly individualized. Peptides are particularly well suited for this approach because they often target very specific signaling pathways. Artificial intelligence is also beginning to accelerate peptide discovery. For decades,

identifying promising peptide sequences required years of laboratory work. Today, advanced computer models can analyze enormous numbers of possible amino acid combinations, predict how they may fold into three -dimensional structures, estimate receptor binding, and identify candidates that are most likely to succeed before they are ever synthesized. This dramatically shortens the discovery process. Scientists can rapidly test thousands of potential designs in silico before selecting

the most promising compounds for laboratory evaluation. That doesn't replace experimental research, but it makes the process much more efficient. Another exciting area involves combination peptide engineering. Instead of designing peptides that influence only one pathway, researchers are exploring multifunctional molecules capable of interacting with several related biological systems simultaneously. We've already seen this concept become successful with newer metabolic medications that activate multiple

hormone receptors. Future apolipoprotein -targeting peptides may eventually incorporate similar design principles. Imagine a molecule that improves cholesterol transport, reduces vascular inflammation, protects endothelial cells, and supports healthy lipid metabolism all at the same time. Whether that becomes reality remains to be seen, but those are the kinds of ideas currently being explored. Researchers are also paying close attention to safety. Any therapy that modifies lipid metabolism

or immune signaling must be evaluated carefully. The cardiovascular system and the immune system are incredibly complex. Improving one pathway while unintentionally disrupting another would not be desirable. That's why extensive clinical testing remains essential before new therapies become widely available. One thing that makes peptide science so fascinating is that it reminds us how interconnected the body truly is. For many years, medicine often separated diseases into different specialties. Cardiology focused

on the heart, neurology focused on the brain, endocrinology focused on hormones, immunology focused on the immune system. We're increasingly discovering that these systems constantly communicate with one another. Inflammation influences cardiovascular disease. Metabolism influences brain health. Immune signaling affects insulin sensitivity. Hormones influence cardiovascular function. The body doesn't recognize the boundaries between medical specialties. It's one integrated biological

system. Apolipoprotein -targeting peptides illustrate that concept beautifully. A molecule initially investigated for cholesterol transport may eventually influence inflammation. A peptide developed for cardiovascular disease may later demonstrate neurological benefits. A compound originally studied in rare lipid disorders may reveal applications in entirely different diseases. Scientific discovery often follows unexpected paths. For those interested in longevity, this area is particularly intriguing.

Healthy aging isn't simply about living longer. It's about preserving function. Maintaining healthy blood vessels, reducing chronic inflammation, supporting normal lipid metabolism, and protecting neurological function all contribute to healthy aging. Whether a polyprotein -targeting peptides ultimately become part of that strategy remains an open question, but they certainly represent one of the more promising areas of ongoing investigation. If you've been following peptide research for a while, you've probably noticed a common theme.

Many of the most exciting compounds aren't designed to overpower biology. Instead, they attempt to restore balance. Rather than forcing the body into an unnatural state, they often enhance processes that already exist. That's true of many regenerative peptides. It's true of several mitochondrial peptides. And it appears to be true of many apolipoprotein mimetic peptides as well. Instead of inventing entirely new biological pathways, researchers

are learning how to strengthen pathways nature already created. That approach may ultimately prove to be one of the most powerful concepts in modern medicine. Although we're still in the early chapters of this story, the pace of discovery continues to accelerate. Every year brings new structural designs, improved delivery systems, better computational models, and deeper understanding of how these remarkable molecules interact with human biology. Some of today's experimental peptides will undoubtedly disappear as research progresses.

Others may evolve into tomorrow's standard therapies. Only careful science will determine which compounds ultimately succeed. For now, apolipoprotein -targeting peptides remain an exciting window into the future of precision medicine, cardiovascular health, neuroscience and peptide engineering. As always, It's important to distinguish between promising research and established clinical evidence. Scientific enthusiasm should always be balanced with scientific rigor. Following the evidence wherever it leads

is what ultimately advances medicine and improves patient care. This podcast is intended for educational and informational purposes only. It is not medical advice and should not be used to diagnose, treat, cure or prevent any disease. Many of the compounds discussed today are investigational and have not been approved for general medical use. Always consult a qualified health care professional before making decisions about your health or using any medication, peptide, or research compound.

Thanks for listening. Keep learning and stay curious.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Retatrutide for Chronic Pain? New Research Reveals Up to 75% Reduction in Knee Arthritis Pain!

    Nov 20, 202633 minAudio

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! 🧬πŸ”₯ RETATRUTIDE FOR CHRONIC PAIN? NEW RESEARCH REVEALS UP TO 75% REDUCTION IN KNEE ARTHRITIS PAIN! Could one of...

    Credit the people on this episode

  2. ICOTYDE: The Breakthrough Oral Peptide Taking on Arthritis β€” No Injections Required!

    Nov 16, 202647 minAudio

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! πŸ§¬πŸ’Š ICOTYDE: THE BREAKTHROUGH ORAL PEPTIDE TAKING ON ARTHRITIS - NO INJECTIONS REQUIRED! Could a simple daily...

    Credit the people on this episode

  3. Retatrutide vs. Ozempic: The Head-to-Head Results Are In β€” Is the Triple Agonist the Future of Weight Loss?

    Nov 13, 202643 minAudio

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! 🧬πŸ”₯ RETATRUTIDE VS. OZEMPIC: THE RESULTS ARE IN! Could the next generation of weight-loss peptides leave Ozempic...

    Credit the people on this episode

  4. The Peptide Comeback: 6 Research Peptides Get a Regulatory Break β€” What You Need to Know

    Nov 11, 202641 minAudio

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! 🧬 The Peptide Comeback: 6 Research Peptides Get a Regulatory Break - What You Need to Know Big news in the...

    Credit the people on this episode

  5. Peptide-Related Death: The Tragic Story of Richard Norton and the Risks of CJC-1295 and Ipamorelin

    Nov 5, 202640 minAudio

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! A Hollywood legend, two experimental peptides, and a fatal allergic reaction. In this episode of The Peptide...

    Credit the people on this episode